These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2530425)

  • 21. Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist.
    Potts RO; Lobo RA
    Obstet Gynecol; 2005 May; 105(5 Pt 1):953-61. PubMed ID: 15863530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hercon technology for transdermal delivery of drugs.
    Shah KR; Ng S; Zeoli L; Haight V; Matz S; Kydonieus AF
    J Biomater Appl; 1986 Oct; 1(2):239-73. PubMed ID: 3146634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estradiol treatment and its interaction with the cholinergic system: effects on cognitive function in healthy young women.
    Bartholomeusz CF; Wesnes KA; Kulkarni J; Vitetta L; Croft RJ; Nathan PJ
    Horm Behav; 2008 Nov; 54(5):684-93. PubMed ID: 18706905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained-release dosage forms.
    Geraets D; Burke T
    Iowa Med; 1990 Mar; 80(3):141-6. PubMed ID: 2180847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous estradiol permeation, penetration and metabolism in pig and man.
    Mahmoud A; Haberland A; Dürrfeld M; Heydeck D; Wagner S; Schafer-Korting M
    Skin Pharmacol Physiol; 2005; 18(1):27-35. PubMed ID: 15608500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Control of drooling using transdermal scopolamine skin patches. A case report.
    Mato Montero A; Limeres Posse J; Tomás Carmona I; Fernández Feijoo J; Diz Dios P
    Med Oral Patol Oral Cir Bucal; 2008 Jan; 13(1):E27-30. PubMed ID: 18167476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: a crossover study with melatonin.
    Bénès L; Claustrat B; Horrière F; Geoffriau M; Konsil J; Parrott KA; DeGrande G; McQuinn RL; Ayres JW
    J Pharm Sci; 1997 Oct; 86(10):1115-9. PubMed ID: 9344167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
    Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skin hypersensitivity reactions to transdermal therapeutic systems--still an important clinical problem.
    Jenerowicz D; Polańska A; Olek-Hrab K; Silny W
    Ginekol Pol; 2012 Jan; 83(1):46-50. PubMed ID: 22384639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute.
    Wokovich AM; Prodduturi S; Doub WH; Hussain AS; Buhse LF
    Eur J Pharm Biopharm; 2006 Aug; 64(1):1-8. PubMed ID: 16797171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro/in vivo functionality of Catapres-TTS.
    Enscore DJ; Osborne JL; Shaw JE
    Methods Find Exp Clin Pharmacol; 1989 Mar; 11(3):173-8. PubMed ID: 2657275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Transdermal estradiol--the possibility for replacement therapy in the postmenopause].
    Rachev E
    Akush Ginekol (Sofiia); 1994; 33(3):45-7. PubMed ID: 7793531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J; Gordon C; Ribak J; Binah O; Rolnick A
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Transdermal and oral hormone substitution with estrogens: a comparison].
    Schindler AE
    Zentralbl Gynakol; 1995; 117(10):504-7. PubMed ID: 7491831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous reactions to transdermal therapeutic systems.
    Musel AL; Warshaw EM
    Dermatitis; 2006 Sep; 17(3):109-22. PubMed ID: 16956462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse dermatologic reactions to transdermal drug delivery systems.
    Hogan DJ; Maibach HI
    J Am Acad Dermatol; 1990 May; 22(5 Pt 1):811-4. PubMed ID: 2112162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of contact dermatitis associated with transdermal therapeutic systems.
    Holdiness MR
    Contact Dermatitis; 1989 Jan; 20(1):3-9. PubMed ID: 2492460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdermal scopolamine in motion sickness.
    Cronin CM; Sallan SE; Wolfe L
    Pharmacotherapy; 1982; 2(1):29-31. PubMed ID: 6927209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.